[HTML][HTML] Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes
Y Mu, X Hao, P Xing, X Hu, Y Wang, T Li… - Journal of cancer …, 2020 - Springer
Purpose Osimertinib, a third-generation epidermal growth factor receptor tyrosine-kinase
inhibitor (EGFR-TKI), has demonstrated substantial clinical benefit in patients with non-small …
inhibitor (EGFR-TKI), has demonstrated substantial clinical benefit in patients with non-small …
Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes
M Yuxin, H Xuezhi, X Puyuan… - Journal of Cancer …, 2020 - search.proquest.com
Purpose Osimertinib, a third-generation epidermal growth factor receptor tyrosine-kinase
inhibitor (EGFR-TKI), has demonstrated substantial clinical benefit in patients with non-small …
inhibitor (EGFR-TKI), has demonstrated substantial clinical benefit in patients with non-small …
Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes
Y Mu, X Hao, P Xing, X Hu, Y Wang, T Li… - Journal of Cancer …, 2020 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Purpose</jats: title>< jats: p>
Osimertinib, a third-generation epidermal growth factor receptor tyrosine-kinase inhibitor …
Osimertinib, a third-generation epidermal growth factor receptor tyrosine-kinase inhibitor …
Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
Y Mu, X Hao, P Xing, X Hu, Y Wang, T Li… - Journal of Cancer …, 2020 - europepmc.org
Purpose Osimertinib, a third-generation epidermal growth factor receptor tyrosine-kinase
inhibitor (EGFR-TKI), has demonstrated substantial clinical benefit in patients with non-small …
inhibitor (EGFR-TKI), has demonstrated substantial clinical benefit in patients with non-small …
Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
Y Mu, X Hao, P Xing, X Hu, Y Wang… - Journal of Cancer …, 2020 - search.ebscohost.com
Purpose: Osimertinib, a third-generation epidermal growth factor receptor tyrosine-kinase
inhibitor (EGFR-TKI), has demonstrated substantial clinical benefit in patients with non-small …
inhibitor (EGFR-TKI), has demonstrated substantial clinical benefit in patients with non-small …
Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes
Y Mu, X Hao, P Xing, X Hu, Y Wang… - Journal of cancer …, 2020 - pubmed.ncbi.nlm.nih.gov
Purpose Osimertinib, a third-generation epidermal growth factor receptor tyrosine-kinase
inhibitor (EGFR-TKI), has demonstrated substantial clinical benefit in patients with non-small …
inhibitor (EGFR-TKI), has demonstrated substantial clinical benefit in patients with non-small …
[HTML][HTML] Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes
Y Mu, X Hao, P Xing, X Hu, Y Wang, T Li… - Journal of Cancer …, 2020 - ncbi.nlm.nih.gov
Purpose Osimertinib, a third-generation epidermal growth factor receptor tyrosine-kinase
inhibitor (EGFR-TKI), has demonstrated substantial clinical benefit in patients with non-small …
inhibitor (EGFR-TKI), has demonstrated substantial clinical benefit in patients with non-small …